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A b s t r a c t
Introduction: The aim of this study was to determine whether baseline right 
ventricular (RV) function assessed by standard echocardiography may indi-
cate patients who will respond to cardiac resynchronization therapy (CRT).
Material and methods: The data of 57 patients (54 men, 95%), aged 66.4 
±8.7 years with heart failure (HF) having a CRT device implanted were col-
lected. All patients had left ventricular ejection fraction (LVEF) ≤ 35% and 
QRS complex duration ≥ 120 ms. Echocardiographic examination with tissue 
Doppler imaging techniques and complex RV evaluation were performed at 
baseline and three months after CRT onset.
Results: Three months after CRT implantation, patients responding to CRT, 
defined as a  reduction of left ventricle end-systolic volume (LVESV) of at 
least 10% (n = 34), compared to patients with a reduction of LVESV of less 
than 10% (n = 23), had at baseline a smaller right atrium diameter (47.85 
±11.33 mm vs. 52.65 ±8.69 mm; p = 0.028), higher TAPSE (14.56 ±2.57 mm 
vs. 13.04 ±2.93 mm; p = 0.030) and lower grade of tricuspid valve regurgita-
tion (1.82 ±0.97 vs. 2.3 ±0.88; p = 0.033). 
Conclusions: This study showed that there are differences in baseline right 
ventricular function between responders and non-responders to CRT. Yet in 
our study, none of the baseline RV parameters provided any value in identi-
fying patients who would respond to CRT.
Key words: cardiac resynchronization therapy, right ventricle, 
echocardiography, heart failure.
Introduction
Cardiac resynchronization therapy (CRT) is a  well-established treat-
ment that improves morbidity and mortality in patients with symptom-
atic, drug refractory heart failure (HF). Cardiac resynchronization therapy 
reverses left ventricular (LV) remodeling, reduces pathological neurohor-
monal activation and improves functional status [1–4]. The effects of 
CRT on LV contractility and synchrony are well-demonstrated, yet little is 
known about the influence of CRT on right ventricular (RV) function [5]. 
It seems that the role of the RV in HF has been thus far underestimated, 
as it was proven to be an independent outcome predictor in patients 
with moderate to severe HF [6]. Studies have also shown that the LV 
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response to CRT may depend on the baseline RV 
performance [7, 8]. Moreover, beneficial effects of 
CRT may be limited by baseline RV function. 
The aim of this study was to compare base-
line RV echocardiographic parameters between 
responders and non-responders to CRT, with the 




A total of 60 consecutive patients who under-
went implantation of a  biventricular pacemaker 
(CRT-P) or defibrillator (CRT-D) for drug-refrac-
tory heart failure (71.9% with an ischemic back-
ground and 28.1% with dilated cardiomyopathy) 
were evaluated. All patients fulfilled current inclu-
sion criteria for CRT (New York Heart Association 
(NYHA) class III–IV despite optimal pharmacolog-
ical treatment, left ventricular ejection fraction 
(LVEF) ≤ 35% and QRS duration ≥ 120 ms). Pa-
tients in NYHA class IV could not have a history of 
hospitalization due to HF exacerbation within one 
month prior to CRT implantation [9]. Inclusion of 
patients with permanent atrial fibrillation in the 
study was only possible if more than 95% of ven-
tricular pacing was achieved. If an adequate level 
of ventricular pacing was impossible to achieve 
with medication, atrioventricular (AV) junction 
ablation was performed. All patients provided 
written informed consent and the study had the 
approval of a  local ethics committee. According 
to the study protocol, all patients were followed 
for 12 weeks. During that time three patients 
died – one due to stroke, one due to myocardi-
al infarction and one of unknown reason. Finally, 
57 patients were studied (54 men – 95%, 3 wom-
en – 5%, aged 66.4 ±8.7 years). Demographic and 
clinical variables of the patient group are present-
ed in Table I.
Device implantation
All CRT implantation procedures were per-
formed under local anesthesia. Leads were placed 
transvenously via the cephalic and/or subclavian 
vein. In the presence of sinus rhythm, CRT-P with 
an atrial lead (setting: DDDR; n = 26) was implant-
ed, while in cases of permanent atrial fibrillation 
no atrial lead (setting: VVIR; n = 13) was placed. 
Patients having a history of cardiac arrest and/or 
malignant ventricular arrhythmias were indicat-
ed for placement of CRT-D (n = 18). For patients 
receiving an atrial lead, placement for each was 
the right atrial (RA) appendage. In 48 patients 
the right ventricular lead was placed in the right 
ventricle outflow tract (RVOT) and in 9 patients in 
the RV apex. No RV lead implanted de novo was 
placed in the RV apex. Right ventricular lead apical 
position was present only in patients in whom CRT 
was an upgrade of a  previously existing device 
(14 cases of device upgrade: VVI – n = 2, DDD – 
n = 9, DDD-ICD – n = 3). In each case a coronary si-
nus venogram was obtained using a balloon cath-
eter followed by insertion of the LV pacing lead. 
The left ventricular lead was directed to a tributary 
of the coronary sinus vein and placed in a stable 
lateral (n = 49) or postero-lateral (n = 8) position, 
with a < 3.5 V capture threshold. The final posi-
tion of the LV pacing lead was assessed with cine 
fluoroscopy. Atrioventricular (AV) delay remained 
on the standard program (120 ms for non-paced 
atrial rhythm/150 ms for paced atrial beat) ex-
cept for the patients with continued ventricular 
Table I. Clinical data and pharmacotherapy of the 
study group (n = 57) – data presented as mean val-
ue with standard deviation (SD) or percentage of 
patients (%)
Parameter Results
Age [years] 66.35 ±8.69
Body mass index (BMI) [kg/m2] 25.82 ±4.15
Male gender, n (%) 54 (94.7)
History of myocardial infarction (%) 64.9
Diabetes (%) 40.4
Hypertension (%) 63.2




Paroxysmal atrial fibrillation (%) 22.8
Permanent atrial fibrillation (%) 17.5
Left bundle branch block (%) 66.6
Anemia (%) 3.5
Smoking (%) 22.8
Chronic kidney disease (%) 31.6
Ischemic background of heart failure 
(%)
71.9
History of coronary artery bypass 
graft (CABG) (%)
14.0




Angiotensin converting enzyme 
inhibitors (ACEi)/angiotensin receptor 
blockers (ARB) (%)
86.0
Loop diuretics (%) 87.8
Digoxin (%) 22.8
Amiodarone (%) 31.6
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conduction, in whom the AV delay was shortened 
until the ventricles were consistently paced (4 cas-
es). A nominal value of 5 ms was left for interven-
tricular (VV) timing, with the left ventricle paced 
first. If no signs of biventricular stimulation in the 
body surface ECG were observed, VV timing was 
changed to elicit QRS fusion beats in ECG lead V1.
Study design
Fifty-seven patients were evaluated prior to 
and 3 months (12–16 weeks) after CRT implan-
tation. Medical history including hospitalizations 
was taken, NYHA class was assessed and a 6-min-
ute walk test (6-MWT) was performed. Echocar-
diographic examinations were performed using 
a GE Vivid 7 device (GE-Vingmed Vivid 7 system; 
GE Vingmed Ultrasound, Horten, Norway). A rou-
tine check-up to assess wound and stimulation 
parameters took place one month after CRT im-
plantation. In one case it was necessary to perform 
AV junction ablation, as 95% of ventricular stimu-
lation was not obtained despite maximal pharma-
cological treatment. Follow-up was than extended 
to 3 months after successful AV junction ablation. 
All study participants underwent coronary angiog-
raphy prior to the CRT procedure. In the presence 
of at least 50% stenosis of one or more coronary 
artery branches or a history of coronary artery by-
pass graft (CABG) or percutaneous coronary inter-
vention (PCI), an ischemic background of conges-
tive heart failure (CHF) was diagnosed.
Echocardiographic assessment
All measurements were obtained following the 
recommendations of the European Association 
of Echocardiography and the American Society 
of Echocardiography [10] at baseline and during 
follow-up. Echocardiographic studies were per-
formed by the same physician and were report-
ed as an average of three measurements. The RV 
dimensions and RA dimensions were estimated 
at end-diastole from a  right ventricle-focused 
apical 4-chamber view. The left parasternal view 
was used for measuring RV wall thickness. Right 
ventricular systolic pressure (RVSP) was estimated 
from tricuspid regurgitation (TR) velocity with the 
addition of RA pressure. Tricuspid annular plane 
systolic excursion (TAPSE) was acquired by placing 
an M-mode cursor through the tricuspid annulus 
and measuring the amount of longitudinal motion 
of the annulus at peak systole. S’, E’ and A’ were 
measured in an apical 4-chamber window with 
a tissue Doppler pulsed sample volume placed in 
the tricuspid annulus. To measure right ventricu-
lar fractional area change (FAC) the endocardial 
border was traced in apical 4-chamber views from 
the tricuspid annulus along the free wall to the 
apex, then back to the annulus, along the inter-
ventricular septum at end-diastole and end-sys-
tole. Trabeculation, tricuspid leaflets, and chords 
were included in the chamber. TR was measured 
by color Doppler as regurgitation jet area and also 
as the percentage of right atrium area covered by 
the regurgitation jet (Table II). 
Presentations were acquired with General Elec-
tric Healthcare Vivid 7 device and included typical 
long- and short-axis and apical views. Acquired 
images were analyzed offline using the commer-
cially available software EchoPAC PC version 6.00 
(GE Vingmed Ultrasound). 
Statistical analysis
Statistical analysis was performed with SAS 
System 9.1 (SAS Institute Inc., Cary, North Caro-
lina, USA). All parameters were tested for normal 
distribution with the Shapiro-Wilk test. Student’s 
t-test or Mann-Whitney-U test was applied to de-
termine whether the parameters’ averages before 
and after the CRT introduction were significantly 
different. Logistic regression analysis was applied 
to assess the odds ratios for predictive values 
of RV parameters using a 95% confidence inter-
val. Statistical significance was considered when 
p < 0.05. A receiver-operating characteristic (ROC) 
curve was generated to determine the predictive 
power of TAPSE for a positive response to CRT.
Results
In the study group, mean NYHA class decreased, 
6-MWT distance increased and mean QRS dura-
tion decreased. The LV diastolic diameter, LV di-
astolic and systolic volumes, RA major diameter, 
RV wall thickness and RV end-systolic area all 
decreased, whereas EF, RV fractional area change 
and TAPSE increased. No differences regarding LV 
end systolic diameter and other RA and RV dimen-
sions were observed.
As many as 34 (59.6%) patients responded 
to CRT according to the applied definition of left 
ventricle end-systolic volume reduction (LVESV) 
≥ 10%. In the group of ischemic HF background 
the response rate equaled 51.2% (21 out of 41 pa-
tients) while in the group of non-ischemic etiology 
it was 81.3% (13 of 16 patients, p < 0.05). Respond-
ers to CRT altogether, as compared to patients 
with no response to CRT (n = 23), had at base-
line a smaller right atrium diameter (47.85 ±11.33 
mm vs. 52.65 ±8.69 mm; p = 0.028), higher TAPSE 
(14.56 ±2.57 mm vs. 13.04 ±2.93 mm; p = 0.030) 
and a lower grade of tricuspid valve regurgitation 
(1.82 ±0.97 vs. 2.3 ±0.88; p = 0.033) (Table III). 
The ROC curve showed that the best cut-off value 
of TAPSE to predict a good response to CRT was 
14 mm with sensitivity of 71%, specificity of 61%, 
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Table II. Clinical outcomes and echocardiographic parameters after CRT implantation
Parameter Directly after implantation (n = 57) 3 months follow-up (n = 57) Value of p
NYHA 3.11 ±0.28 2.25 ±0.68 < 0.001
6-MWT [m] 298.04 ±107.42 373.12 ±127.15 < 0.001
QRS [ms] 184.23 ±28.31 152.70 ±19.11 < 0.001
LVEDd [mm] 73.33 ±8.94 71.54 ±9.87 0.005
LVESd [mm] 62.40 ±10.03 60.60 ±11.29 0.081
LVEF (%) 21.70 ±4.81 26.05 ±4.86 < 0.001
LVEDV [ml] 244.30 ±83.79 226.42 ±88.61 < 0.001
LVESV [ml] 192.79 ±71.95 168.67 ±76.48 < 0.001
RA minor dimension [mm] 37.67 ±7.39 36.42 ±6.18 0.116
RA major dimension [mm] 49.79 ±10.53 48.33 ±9.47 0.040
RA end-systolic area [cm2] 17.49 ±6.30 17.06 ±5.91 0.155
RV wall thickness [mm] 5.47 ±1.20 5.12 ±1.02 0.028
RV longitudinal dimension [mm] 25.35 ±7.02 25.84 ±6.37 0.342
RV basal dimension [mm] 28.74 ±4.47 28.32 ±4.24 0.266
RV mid cavity dimension [mm] 24.21 ±4.85 23.75 ±5.20 0.160
RV end-diastolic area [cm2] 15.72 ±5.20 15.62 ±5.45 0.927
RV end-systolic area [cm2] 10.94 ±4.51 10.22 ±4.25 0.007
RV fractional area change (%) 31.35 ±10.32 35.40 ±10.51 < 0.001
TAPSE [mm] 13.95 ±2.80 15.79 ±2.33 < 0.001
S’ [cm/s] 8.84 ±3.45 11.00 ±3.43 < 0.001
RA – right atrium, RV – right ventricle, TAPSE – tricuspid annular plane systolic excursion, S’ – peak systolic annular velocity, E’ – peak early 
diastolic annular velocity, A’ – peak late diastolic annular velocity, TR – tricuspid regurgitation, TR%RA – percentage of right atrium area 
covered by regurgitation jet, RVSP – right ventricle systolic pressure. *Only in patients with sinus rhythm.
Table III. Baseline echocardiographic parameters in responders and non-responders to CRT
Parameter Non-responders (n = 23) Responders (n = 34) Value of p
RA minor dimension [mm] 38.35 ±7.08 37.21 ±7.66 0.489
RA major dimension [mm] 52.65 ±8.69 47.85 ±11.33 0.028
RA area [cm2] 19.01 ±5.70 16.47 ±6.57 0.064
RV wall thickness [mm] 5.78 ±1.24 5.26 ±1.14 0.309
RV diastole [mm] 26.3 ±8.08 24.71 ±6.25 0.660
RV systole [mm] 21.74 ±7.96 19.85 ±6.56 0.499
RV basal minor dimension [mm] 28.83 ±4.67 28.68 ±4.40 0.987
RV mid cavity dimension [mm] 23.83 ±4.74 24.47 ±4.97 0.858
RV 4CH  systolic area [cm2] 11.07 ±4.61 10.86 ±4.51 0.776
RV 4CH diastolic area [cm2] 15.76 ±5.60 15.69 ±5.00 0.884
RV fractional area change (%) 30.91 ±8.42 31.65 ±11.54 0.948
TAPSE [mm] 13.04 ±2.93 14.56 ±2.57 0.030
S’ [cm/s] 8.17 ±3.27 9.29 ±3.55 0.269
E’ [cm/s]* 7.52 ±3.33 8.24 ±2.94 0.323
A’ [cm/s]* 8.43 ±4.26 10.53 ±4.91 0.126
TR 2.30 ±0.88 1.82 ±0.97 0.033
TR%RA (%) 23.52 ±11.43 18.03 ±11.74 0.051
RVSP [mm Hg] 33.95 ±22.56 29.13 ±18.96 0.087
RA – right atrium, RV – right ventricle, TAPSE – tricuspid annular plane systolic excursion, S’ – peak systolic annular velocity, E’ – peak early 
diastolic annular velocity, A’ – peak late diastolic annular velocity, TR – tricuspid regurgitation, TR%RA – percentage of right atrium area 
covered by regurgitation jet, RVSP – right ventricle systolic pressure. *Only in patients with sinus rhythm.
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negative predictive value (NPV) of 58% and positive 
predictive value (PPV) of 73% (Figure 1; Table IV). 
Of the RV echocardiographic parameters assessed 
at baseline, no single parameter was able to pro-
vide a  statistically significant predictive value of 
response to CRT.
Discussion
The major finding of the current study is that 
patients responding to CRT have better baseline 
RV function, especially systolic function assessed 
by TAPSE measurements. Yet there is no single RV 
parameter that could indicate patients who are 
likely to respond to CRT.
Figure 1. ROC curve showing best cut-off point of 














           1-Specificity
Cardiac resynchronization therapy undoubtedly 
has a positive effect on RV function [11]. Left ven-
tricular ejection fraction remains the most import-
ant echocardiographic parameter in selecting pa-
tients for CRT. However, there is a constant need to 
find additional parameters, as a large percentage 
of patients still do not benefit from CRT. Right ven-
tricular dysfunction markers may indicate more 
severe heart disease, and in the presence of low 
LVEF reflect poorer global function of heart muscle. 
In this situation improving myocardial synchrony 
may be of only limited significance.
Response to cardiac resynchronization 
therapy and baseline right ventricular 
function
In our study we decided to define response to CRT 
as having at least a 10% reduction of end-systolic 
diameter (LVESD). This definition of CRT response 
is proven to correlate with better long-term survival 
and all-cause mortality reduction regardless of HF 
etiology [12]. According to selected criteria, the re-
sponse rate in our study group was 60%, which is in 
concordance with the available literature [13].
It is still not yet well established how right ven-
tricle baseline function affects the response to CRT. 
Data from recent studies demonstrate that some 
parameters assessing RV function may have poten-
tial to indicate patients who will respond to CRT. 
Among them is the TAPSE. Tricuspid annular plane 
systolic excursion is simple to measure, does not re-
quire special equipment or prolonged examination, 
is less dependent on optimal image quality and is 
reproducible [14]. Moreover, it has a good correla-
tion with radionuclide-derived RVEF. Echocardio-
Table IV. Cut-off values of TAPSE for predicting response to CRT
TAPSE Sensitivity Specificity PPV NPV
22 0.029 1.000 1.000 0.411
20 0.029 0.957 0.500 0.400
19 0.118 0.957 0.800 0.423
18 0.118 0.913 0.667 0.412
17 0.147 0.870 0.625 0.408
16 0.265 0.870 0.750 0.444
15 0.471 0.739 0.727 0.486
14 0.706 0.609 0.727 0.583
13 0.765 0.478 0.684 0.579
12 0.941 0.261 0.653 0.750
11 0.941 0.130 0.615 0.600
10 1.000 0.043 0.607 1.000
TAPSE – tricuspid annular plane systolic excursion, PPV – positive predictive value, NPV – negative predictive value.
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Table V. Predictive value of selected RV echocardio-
graphic parameters in responders to CRT
Parameter OR 95% CI
RA minor dimension [mm] 0.979 (0.91–1.05)
RA major dimension [mm] 0.956 (0.91–1.01)
RA area [cm2] 0.936 (0.86–1.02)
RV wall thickness [mm] 0.681 (0.42–1.10)
RV diastole [mm] 0.968 (0.90–1.05)
RV systole [mm] 0.963 (0.89–1.04)
RV basal minor dimension 
[mm]
0.992 (0.88–1.12)
RV mid cavity dimension 
[mm]
1.029 (0.92–1.15)
RV 4CH  systolic area [cm2] 0.990 (0.88–1.11)
RV 4CH diastolic area [cm2] 0.998 (0.90–1.11)
RV FAC (%) 1.007 (0.96–1.06)
TAPSE [mm] 1.249 (1.00–1.57)
S’ [cm/s] 1.105 (0.94–1.30)
E’ [cm/s]* 1.080 (0.91–1.29)
A’ [cm/s]* 1.107 (0.98–1.25)
TR 0.577 (0.32–1.04)
TR%RA (%) 0.960 (0.92–1.01)
RVSP [mm Hg] 0.988 (0.96–1.02)
RA – right atrium, RV – right ventricle, TAPSE – tricuspid annular 
plane systolic excursion, TR – tricuspid regurgitation, TR%RA 
– percentage of right atrium area covered by regurgitation jet, 
S’ – peak systolic annular velocity, E’ – peak early diastolic annular 
velocity, A’ – peak late diastolic annular velocity, RVSP – right 
ventricle systolic pressure. *Only in patients with sinus rhythm.
graphic data from CARE-HF show that in patients 
with baseline TAPSE of ≤ 14 mm, after 18 months 
of follow-up there is less improvement in LVEF and 
LVESV. In CARE-HF, unlike intraventricular mechan-
ical delay and etiology of HF, TAPSE was an inde-
pendent predictor of echocardiographic response. 
CARE-HF focused only on selected RV parameters, 
mostly assessing LV function. In our study TAPSE 
was of borderline significance as an independent 
predictor of echocardiographic response (Table V).
Patients responding to CRT in our study had 
higher TAPSE value at baseline. In our study the 
cut-off point for response to CRT was 14 mm, be-
low the standard echocardiographic cut-off value 
of 15 mm. Tricuspid annular plane systolic excur-
sion is the most described alternative to right ven-
tricular ejection fraction (RVEF) estimation, which 
is often challenging due to the RV being a com-
plex structure. There is also growing evidence that 
TAPSE may help identify patients who would re-
spond to CRT [15–17], with some studies showing 
this parameter to be even a potential prognostic 
marker of major adverse events [16]. A low TAPSE 
value may indicate poor RV performance, which 
may reflect more extensive and severe heart dis-
ease. In such cases, improving myocardial syn-
chrony may not give clinically significant benefits. 
In our opinion, the clinical value of this parameter 
requires further investigation. 
Our observation also showed that a  lower 
grade of tricuspid regurgitation (TR) may indicate 
patients with a less favorable response to CRT. In 
adults, TR is usually a consequence of left-sided 
valvular lesions or chronic pulmonary disease. In 
patients with advanced heart failure, there is el-
evated LV filling pressure and mitral regurgitation 
(MR) due to ventricle dilatation. Lower grades of 
TR may reflect less remodeling of LV and indicate 
patients who will potentially benefit from CRT. 
Kanzaki et al. found in their study on 26 patients 
undergoing CRT implantation that resynchroniza-
tion therapy immediately reduces MR, regurgitant 
volume and regurgitant fraction. Mitral regurgi-
tation reduction results in decreased pressure in 
pulmonary arteries and lower RV afterload [18]. 
This mechanism might be responsible for the 
improvement of TR observed in our study. More-
over, TR grade and area of regurgitation wave to 
the right atrium correlated positively in our study 
with LVESV reduction in the entire study popu-
lation. Some studies have shown that increased 
pulmonary artery pressure is associated with 
non-response to CRT [7]. This observation was not 
confirmed in our study. While there was a differ-
ence in pulmonary pressure at baseline between 
responders and non-responders to CRT, statistical 
significance was not reached.
Results from a study to evaluate right ventri-
cle function in patients undergoing cardiac re-
synchronization therapy conducted by Scuteri et 
al. showed that all echocardiographic indices of 
baseline RV function and dimensions were sig-
nificantly more impaired in non-responders to 
CRT [7]. This was reported to be true not only for 
TAPSE, but also for RVSP, RV end-systolic and dia-
stolic areas and RV fractional area change. These 
results were not confirmed in our observation. 
Such a difference might be explained not only by 
different duration of follow-up period, which in 
our case was 3 months, while it was 6 months in 
the Italian study. Also, Scuteri et al. chose a dif-
ferent CRT response criterion, which was LVESD 
reduction of at least 15% after 6 months of 
biventricular stimulation. The Italian cohort was 
smaller and only about one third of patients had 
an ischemic background of HF, while in our group 
two thirds of patients did. 
The clinical predictive value of selected base-
line RV parameters was not statistically signifi-
cant, with TAPSE being the only parameter close 
to reaching significance. The small difference in 
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baseline TAPSE in responders and non-responders 
to CRT made even this parameter of no predictive 
value in any single patient. 
The PROSPECT study showed that no single 
echocardiographic measure of dyssynchrony may 
be recommended to improve patient selection for 
CRT. This was reported to be the result of variabil-
ity from technical and interpretative factors [19]. 
Cardiac resynchronization therapy procedural 
factors such as lead location, which may not be 
optimal in some cases due to coronary venous 
anatomy, may also limit the predictive value of 
echocardiography. Taking further into account the 
limitations of our study (small study group, short 
observation period), we still believe that some RV 
parameters, especially TAPSE, might prove to be 
useful in CRT candidate selection. 
In conclusion, this study showed that there are 
differences in baseline right ventricular function 
between responders and non-responders to CRT. 
Yet in our study, none of the individual baseline 
RV parameters showed any value in identifying 
patients who would respond to CRT. 
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